KBI Biopharma, Inc. – FDA 483, Dec 3, 2021
KBI Biopharma, Inc. in Boulder, CO, a drug substance manufacturer, received a Form 483 citing two observations related to quality control deficiencies. The firm failed to conduct complete investigations into contamination events within its water generation system, often leaving root causes undetermined. Additionally, equipment maintenance procedures were found to be deficient, with critical processing equipment lacking established cleaning schedules and numerous pressure gauges remaining uncalibrated.
ID · 5239f5c8-755b-47b0-ba48-fbecb11890fe
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.